InvestorsHub Logo
Followers 14
Posts 2866
Boards Moderated 0
Alias Born 12/23/2014

Re: Jlivermore29 post# 11

Monday, 11/04/2019 3:18:30 PM

Monday, November 04, 2019 3:18:30 PM

Post# of 461
seems to me people are buying in, believing that the earnings will be good.

One thing I have not seen talked about is the new Chairman of the Board, John Fletcher. I suspect what was orchestrated before and during the last conference(Re branding, new product launch) as having his stamp.

Mr. Fletcher brings more than 35 years of healthcare and medical device experience to RMS Medical. He currently serves as CEO and Managing Director of Fletcher Spaght Inc., a strategy consulting and venture capital firm which he founded in 1983. Prior to founding Fletcher Spaght, he was Senior Manager at The Boston Consulting Group, advising a broad range of companies in healthcare and high technology industries.

Mr. Fletcher joined the Board of Directors of publicly-traded medical device company Spectranetics Corporation in 2002 and served as Chairman of the Board from 2010-2017. During his 15-year tenure as a member of the board, Spectranetics expanded its therapeutic platforms and generated significant commercial growth. In August 2017 Spectranetics was acquired by Royal Philips in a transaction valued at $2.2 billion.[color=red][/color] Mr. Fletcher was named 2018 Director of the Year by The National Association of Corporate Directors (NACD) for his work at Spectranetics.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent KRMD News